Methylene blue for septic shock in oncologic patients: A propensity score-matched cohort. (2026)

Peer-Reviewed Study · Melo RH, Galantier J, Romano MLP, Romano ER, Felicio APV, da Hora Passos R, Gioli-Pereira L, de Azevedo LCP · May 3, 2026

Melo RH et al., 2026-05-03: Propensity-matched retrospective cohort (TriNetX, 2015-2025) of oncologic patients in septic shock in which methylene blue was associated with lower 30-day mortality (RR 0.80).

Among 266 MB-treated patients and 10,163 controls, 262 balanced pairs were analyzed after matching.

Melo RH et al., 2026-05-03: Propensity-matched retrospective cohort (TriNetX, 2015-2025) of oncologic patients in septic shock in which methylene blue was associated with lower 30-day mortality (RR 0.80). C5 (observational). Study type: retrospective propensity-score-matched cohort using the TriNetX Research Network, 266 methylene-blue-treated patients vs 10,163 controls, 262 matched pairs; Hospital Israelita Albert Einstein, Sao Paulo, Brazil. Outcome: 30-day mortality RR 0.80 (95% CI 0.66-0.97); favourable associations for AKI and vasopressor escalation; no difference in invasive ventilation. Dose not stated in the abstract. Disclosures: the authors declare financial interests/relationships per the record (business ties noted neutrally). Comparator: matched controls without methylene blue. J Crit Care 2026;94:155607. Study type: controlled study.